drugset / Trial / NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease. This research is being done because there is no completely safe and effective prevention for graft-versus-host disease. It is known that cyclosporine helps with GVHD but we would like to know if the addition of basiliximab will decrease the incidence and/or severity of GVHD after a transplant known as nonmyeloablative ("mini" transplant).
Timeline
- Start
- 2007-10
- Primary completion
- 2008-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basiliximab | Monoclonal antibody | 20 mg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | — |
| Background | Cyclosporine | Peptide | 3 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |
| Background | Mycophenolate Mofetil | Small molecule | 1000 mg | — |